In the following video, Motley Fool health-care analyst David Williamson explains what's behind a massively important trial for Vertex Pharmaceuticals . The company's cystic fibrosis drug Kalydeco currently treats only about 4% of the population, but Vertex is looking to apply the drug to a more common mutation of the disease, which would expand the drug's reach to be effective for nearly half of the CF patient population. David tells investors just how much money is at stake in this market, and what's at stake if the trial doesn't go as planned.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report " 3 Stocks That Will Help You Retire Rich " names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Vertex Enters Critical Phase originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.